A Phase I Randomized Study of a Specifically Engineered, pH‐Sensitive PCSK9 Inhibitor RN317 (PF‐05335810) in Hypercholesterolemic Subjects on Statin Therapy

od Levisetti, M, Joh, T, Wan, H, Liang, H, Forgues, P, Gumbiner, B, Garzone, PD
izdano v Clin Transl Sci (2016)